Back to results
US 2025/0249084 A1Published application
Alphavirus antigen vectors
AssigneeGritstone Bio, Inc.
InventorsWade Blair, Karin Jooss, Amy Rachel Rappaport, Ciaran Daniel Scallan, Leonid Gitlin
Life of this patent
Estimating the term…
Abstract
Disclosed herein are alphavirus vectors that include neoantigen-encoding nucleic acid sequences derived from a tumor of a subject. Also disclosed are nucleotides, cells, and methods associated with the vectors including their use as vaccines.
Claims24
1-173. (canceled)
A method for inducing an immune response in a subject, comprising:
- (A) administering a first vaccine composition, wherein the first vaccine composition comprises a vector encoding a first neoantigen-encoding nucleic acid sequence;
- and
- (B) administering a second vaccine composition, wherein the second vaccine composition comprises a RNA vector encoding a second neoantigen-encoding nucleic acid sequence,
- wherein the vector encoding the first neoantigen-encoding nucleic acid sequence is not a RNA vector.
1 more element
Dependencies are inferred from the claim text.